Positive NOVARAD study results could herald “new era” for radiation protection

Cathpax Nova-X Radiation Protection System Studied for Interventional Neuroradiology Procedures

January 21, 2026—Cathpax, a Nantes, France-based spin-off of the Lemer Pax group, announced the results of the NOVARAD clinical study evaluating exposure to x-rays in interventional neuroradiology. According to Cathpax, the NOVARAD study aims to assess the effectiveness of the company’s Nova-X system in head-to-toe protection from exposure to x-rays during interventional procedures for the entire team in catheterization labs. Nova-X received CE …

Positive NOVARAD study results could herald “new era” for radiation protection

Nova-X Cathpax—a spinoff of the Lemer Pax group that designs, develops and commercialises team-wide, full-body radiation protection systems for interventional medicine practitioners—has today announced positive results from the NOVARAD clinical study. This study is described by the company as the “first ever” to evaluate exposure to X-rays in interventional neuroradiology, with the aim of assessing the effectiveness of Nova-X in protecting the e…